Senate Panel Clears Azar; Drug Lobbyists Criticize His Part B Views

By John Wilkerson / January 17, 2018 at 8:01 PM
The Senate Finance Committee on Wednesday (Jan. 17) cleared the nomination of Alex Azar to HHS secretary for a floor vote, but Democrats voted against Azar because he was president of Eli Lilly USA while the company significantly raised drug prices . One of Azar's suggestions for curbing drug-price growth is allowing pharmacy benefit managers to negotiate prices in Medicare Part B as they do in Part D, but some drug lobbyists say that's an ironic position for two reasons:...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.